Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Menlo Therapeutics Inc (MNLO)

Menlo Therapeutics Inc (MNLO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 113,298
  • Shares Outstanding, K 23,953
  • Annual Sales, $ 10,640 K
  • Annual Income, $ -51,450 K
  • 60-Month Beta 2.39
  • Price/Sales 10.24
  • Price/Cash Flow N/A
  • Price/Book 1.07

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.79
  • Number of Estimates 3
  • High Estimate -0.75
  • Low Estimate -0.85
  • Prior Year -0.56
  • Growth Rate Est. (year over year) -41.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.69 +67.66%
on 08/14/19
5.18 -12.93%
on 08/22/19
+0.35 (+8.41%)
since 07/23/19
3-Month
2.69 +67.66%
on 08/14/19
7.00 -35.57%
on 05/30/19
-2.24 (-33.19%)
since 05/23/19
52-Week
2.69 +67.66%
on 08/14/19
12.00 -62.42%
on 09/19/18
-3.48 (-43.55%)
since 08/23/18

Most Recent Stories

More News
Menlo Therapeutics Reports Second Quarter 2019 Financial Results and Provides Program Updates Including Accelerated Timeline for Upcoming Clinical Data

Results from Serlopitant Phase 2 Clinical Trial for the Treatment of Chronic Pruritus of Unknown Origin Anticipated in Q1 2020

MNLO : 4.51 (-4.65%)
Menlo Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference

Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta, Menlo's...

MNLO : 4.51 (-4.65%)
Life Science Company Live Investor Presentations Now Available for On-Demand Viewing

Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the July 11th life sciences conference are now available for on-demand viewing...

MNLO : 4.51 (-4.65%)
NGW.CN : 0.255 (+4.08%)
LXX.CN : 0.930 (-9.71%)
Life Science Company Live Investor Conference July 11th

Life science company executives will share vision and answer audience questions at VirtualInvestorConferences.com

MNLO : 4.51 (-4.65%)
NGW.CN : 0.255 (+4.08%)
LXX.CN : 0.930 (-9.71%)
Menlo Therapeutics to Present at Upcoming Investor Conferences

Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta, Chief Executive...

MNLO : 4.51 (-4.65%)
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Menlo Therapeutics, Inc. of Class Action Lawsuit

The following statement is being issued by Levi & Korsinsky, LLP:

MNLO : 4.51 (-4.65%)
Menlo Therapeutics Reports First Quarter 2019 Financial Results

Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced financial results for the...

MNLO : 4.51 (-4.65%)
Menlo Therapeutics to Present at the Class of 2018 Biotech IPOs Investor Day

Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta, Chief Executive...

MNLO : 4.51 (-4.65%)
New Research: Key Drivers of Growth for Geron, Hess, Royal Gold, Lear, Menlo Therapeutics, and CorEnergy Infrastructure Trust -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Geron Corporation (NASDAQ:GERN),...

MNLO : 4.51 (-4.65%)
CORR : 45.05 (-0.86%)
HES : 59.56 (-6.86%)
LEA : 106.50 (-3.67%)
GERN : 1.36 (-5.56%)
RGLD : 129.35 (+2.08%)
Menlo Therapeutics Announces Publication of Serlopitant Phase 2 Data for the Treatment of Pruritus Associated with Prurigo Nodularis

Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced the publication of the company's...

MNLO : 4.51 (-4.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade MNLO with:

Business Summary

Menlo Therapeutics Inc. is a late stage biopharmaceutical company. It focused on the development of serlopitant and treatment of chronic itch and chronic refractory cough. The company's product pipeline consists of Prurigo Nodularis Itch, Atopic Dermatitis Itch, Psoriasis Itch and Refractory Chronic...

See More

Key Turning Points

2nd Resistance Point 4.96
1st Resistance Point 4.73
Last Price 4.51
1st Support Level 4.39
2nd Support Level 4.28

See More

52-Week High 12.00
Fibonacci 61.8% 8.44
Fibonacci 50% 7.35
Fibonacci 38.2% 6.25
Last Price 4.51
52-Week Low 2.69

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar